Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accumulated Expenses (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Accumulated Expenses data on record, last reported at $819000.0 in Q2 2025.

  • For Q2 2025, Accumulated Expenses changed N/A year-over-year to $819000.0; the TTM value through Jun 2025 reached $819000.0, changed N/A, while the annual FY2024 figure was $3.7 million, 6.17% down from the prior year.
  • Accumulated Expenses reached $819000.0 in Q2 2025 per CRVS's latest filing, down from $3.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $7.5 million in Q4 2022 and bottomed at $751000.0 in Q3 2023.
  • Average Accumulated Expenses over 4 years is $3.7 million, with a median of $4.0 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: plummeted 47.4% in 2023, then soared 461.25% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $7.5 million in 2022, then tumbled by 47.4% to $4.0 million in 2023, then decreased by 6.17% to $3.7 million in 2024, then crashed by 78.01% to $819000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $819000.0 in Q2 2025, $3.9 million in Q1 2025, and $3.7 million in Q4 2024.